NeuroMetrix (NASDAQ:NURO) Shares Cross Above Two Hundred Day Moving Average – Here’s What Happened

NeuroMetrix, Inc. (NASDAQ:NURO)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.21 and traded as high as $4.69. NeuroMetrix shares last traded at $4.55, with a volume of 35,522 shares changing hands.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of NeuroMetrix in a research report on Wednesday. They set a “sell” rating for the company.

NeuroMetrix Stock Performance

The firm has a 50 day moving average of $4.41 and a two-hundred day moving average of $4.21. The stock has a market cap of $9.37 million, a P/E ratio of -0.99 and a beta of 1.82.

Institutional Investors Weigh In On NeuroMetrix

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new stake in NeuroMetrix in the 4th quarter valued at $46,000. Deltec Asset Management LLC acquired a new position in shares of NeuroMetrix during the first quarter valued at about $81,000. Finally, GTS Securities LLC bought a new stake in shares of NeuroMetrix in the fourth quarter valued at about $90,000. Institutional investors and hedge funds own 19.40% of the company’s stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.